生物学的製剤投与中の関節リウマチ患者における手術症例の検討
スポンサーリンク
概要
- 論文の詳細を見る
Purpose: We set out to evaluate the peri- and postoperative status of rheumatoid arthritis patients treated by biologic disease-modifying antirheumatic drugs (DMARDs).Methods: Twenty-five surgical procedures in 19 rheumatoid arthritis patients were analyzed. The patients had a mean age of 55.3 (39-76) years, a disease duration of 163 (26-480) months, and a follow-up period after surgery of 21 (5-48) months. Infliximab (IFX) was administrated in 8 cases and etanercept (ETN) in 17 cases.Results: Artificial arthroplasty was performed in 15 cases (knee 9, shoulder 2, elbow 2, and finger 2) synovectomy in 2, wrist joint arthroplasty in 2, forefoot surgery in 2, and others in 4. Pre- and postoperative interruption of biologics was 4 weeks in IFX cases and 2 weeks in ETN cases. Adverse events were found in 2 cases (8%, ETN 1, IFX 1): surgical site infection of superficial incisional site at 37 days after total knee arthroplasty followed by debridement, and deep infection of total knee arthroplasty at 22 months after total knee arthroplasty followed by open synovectomy and local perfusion. ETN was administrated again after 2 weeks and IFX after 13 months, respectively, because of severe joint arthritis.Conclusion: For patients receiving biologic DMARDs, careful peri- and postoperative management for infection of the incisional surgical site is necessary during continuous postsurgical follow-up as well as when undergoing orthopedic surgery.
- 日本関節病学会の論文
日本関節病学会 | 論文
- 関節リウマチ患者における手術と機能回復
- 低出力超音波刺激(LIPUS)および線維芽細胞増殖因子(FGF-2)の骨形成促進作用におけるヒアルロン酸(HA)の影響
- 変形性関節症に対するグルコサミン・コンドロイチンの有用性 (第36回[日本関節病]学会寄稿)
- 人工膝関節再置換術の経験--脛骨結節骨切り術の適応と合併症について
- RA頚椎病変に対する上位頚椎後方除圧固定術の治療成績と問題点